Abstract
Bone remodeling is a complex but coupled process in which old bone is resorbed, followed by the formation of new bone. Ten percent of the human skeleton is remodeled per year. Osteoporosis is a disorder of bone remodeling characterized by uncoupling of resorption from formation. The net result is a loss of bone mass. Pharmacologic agents can restore bone mass by inhibiting bone resorption or stimulating new bone formation; antiresorptive agents suppress osteoclast-mediated dissolution more than bone formation, resulting in a secondary increase in bone mineral density (BMD). This alters the remodeling sequence and strengthens bone by reducing microperforations. In turn, osteoporotic fractures of the hip and spine are reduced. At the present time, virtually all drugs, except one, that are approved by the US Food and Drug Administration (FDA) for the treatment of established osteoporosis act to inhibit bone resorption. These include calcitonin, estrogen, raloxifene (Evista; Lilly, Indianapolis, IN), risedronate, and alendronate.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Riggs BL: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322:802–809.
Neer RM, Arnaud CD, Zanchetta JR, et al: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.
Mitlak BH, Burdette-Miller R Schoenfeld D, Neer RM: Sequential effects of chronic human PTH treatment of estrogen deficiency osteopenia in the rat. J Bone Miner Res 1996, 11:430–439.
Finkenstedt G, Gasser RW, Hofle G, et al: Effects of GH replacement on bone metabolism and bone mineral density in adult onset of G H deficiency: results of a double-blind placebo controlled study with open follow-up. Eur J Endocrinol 1997, 136:282–289.
Boonen S, Rosen C, Bouillon R, et al: Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab 2002, 87:1593–1599.
Rosen CJ, Donahue LR, Hunter SJ: IGFs and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994, 206:83–101.
Beamer WG, Donahue LR, Rosen CJ, Baylink DJ: Genetic variability in adult bone density among inbred strains of mice. Bone 1996, 18:397–405.
Rosen CJ, Dimai HR Vereault D, et al.: Circulating and skeletal IGF-I concentrations in two inbred strains of mice with different bone densities. Bone 1997,21:217–223.
Dimai HR Linkhart TA, Linkhart SG, et al: Alkaline phosphatase levels and osteoprogenitor cell numbers suggest that bone formation may contribute to peak bone density differences between two inbred strains of mice. Bone 1998, 22:211–216.
Bachrach LK, Marcus R, Ott SM, et al: Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. J Bone Miner Res 1998, 13:415–421.
Kiel DP, Puhl J, Rosen CJ, et al: Lack of an association between IGF-I and body composition, muscle strength, physical performance, or self-reported mobility among older persons with functional limitations. J Am Geriatr 1998,46:822–828.
Harris TB, Kiel DP, Roubenoff R, et al: Association of IGF-I with body composition, weight history and past health behaviors in the very old. J Am Geriatr Soc 1997, 45:133–139.
Kurland E, Rosen CJ, Cosman F, et al: Osteoporosis in men: abnormalities in the IGF-I axis. J Clin Endocrinol Metab 1997,82:2799–2805.
Rail LC, Rosen CJ, Dolnikowski G, Hartman WJ, Roubenoff R: Protein metabolism in rheumatoid arthritis and aging. Arthritis Rheum 1996, 39:1115–1124.
Roubenoff R, Rail LC Veldhuis JD, et al: The relationship between GH kinetics and sarcopenia in postmenopausal women: the role of fat mass and leptin. J Clin Endocrinol Metab 1998,83:21–24.
Maclean DB, Kiel DP, Rosen CJ: Low dose GH for frail elders stimulates bone turnover in a dose dependent manner. J Bone Miner Res l995(Suppl), 10:S48.
Holloway L, Kohlmeier L, Kent K, Marcus R: Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab 1997,82:111–1117.
Reeve J: PTH: a future role in the management of osteoporosis. J Bone Miner Res 1996, 11:440–445.
Sogaard CH, Mosekilde L,Thomsen SJ, et al: A comparison of the effects of two anabolic agents (NaF and PTH) on ash density and bone strength assessed in an osteopenic rat model. Bone 1997, 20:439–449.
Watson R Lazowski D, Han V, Hodsman AH: PTH restores bone mass and enhances osteoblast IGF-I gene expression in ovariectomized rats. Bone 1995, 16:357–365.
Lindsay R, Nieves J, Formica C, et al: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997,350:550–555.
Ammann R Rizzoli R, Caverzasio PS, Bonjour JP: Fluoride potentiates the osteogenic effects of IGF-I in aged ovariectomized rats. Bone 1998, 22:39–43.
Zerwekh JE, Padalino R Pak CYC:The effect of intermittent slow release NaF and continuous calcium citrate therapy on calciotropic hormones, biochemical markers of bone metabolism, and blood chemistry in postmenopausal osteoporosis. Calcif Tissue Int 1997, 61:272–278.
Meunier PJ, Sebert JL, Reginster JY, et al: Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis.The FAVO study. Osteoporosis Int 1998,8:4–12.
Rittmaster RS, Bolognaise M, Ettinger MP, et al: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129–2134.
Recommended Reading
Bondy CA: Clinical uses of IGF-I. Ann Intern Med 1994, 120:593–601.
Ebeling PR, Jones JD, O’ Fallon WM, et al.: Short-term effects of recombinant human IGF-I on bone turnover in normal women. Clin Endocrinol Metab 1993,77:1384–1391.
Ghiron LJ, Thomspon JL, Holloway L, et al: Effects of recombinant IGF-I and GH on bone turnover in elderly women. J Bone Miner Res 1995 10:1844–1854.
Johansson AJ, Rosen CJ:The IGFs: potential anabolic agents for the skeleton. In Anabolic Treatments for Osteoporosis. Edited by Whitfield JF, Morley P. New York: CRC Press; 1998; 185–201.
Nicholas V, Prewett A, Bettica R et al: Age-related decreases in IGF-I and TGF-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab 1994 78:1011–1020.
Rosen CJ: Insulin-like growth factor-l and PTH: potential new therapeutic agents for the treatment of osteoporosis. Exp Opin Invest Drugs 1997 9:1193–1198.
Rubin J, Ackert-Bicknell CL, Zhu L, et at.: IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 2002, 87:4273–4279.
Tritos NA, Mantzoros CS: Recombinant human growth hormone: old and novel uses. Am J Med 1998, 105:44–57.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rosen, C.J. (2003). Bone Anabolic Agents. In: Orwoll, E.S. (eds) Atlas of Osteoporosis. Current Medicine Group, London. https://doi.org/10.1007/978-1-4757-4561-0_17
Download citation
DOI: https://doi.org/10.1007/978-1-4757-4561-0_17
Publisher Name: Current Medicine Group, London
Print ISBN: 978-1-4757-4563-4
Online ISBN: 978-1-4757-4561-0
eBook Packages: Springer Book Archive